Cargando…

212P A cohort study on the immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer: Does trastuzumab interfere with the outcome?

Detalles Bibliográficos
Autores principales:	Javadinia, S.A., Dehghani, M., Ariamanesh, M., Roudsarabi, Z.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Society for Medical Oncology. Published by Elsevier Ltd. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9069431/ http://dx.doi.org/10.1016/j.annonc.2022.03.233

Ejemplares similares

A Cohort Study on the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients With Breast Cancer; Does Trastuzumab Interfere With the Outcome?
por: Joudi, Maryam, et al.
Publicado: (2022)

BBIBP-CorV: Hepatitis: case report
Publicado: (2022)

BBIBP-CorV: Anterior uveitis: case report
Publicado: (2022)

Persistence of immune responses to the Sinopharm/BBIBP‐CorV vaccine
por: Jeewandara, Chandima, et al.
Publicado: (2022)

BBIBP-CorV: Steven-Johnson syndrome : case report
Publicado: (2022)

BBIBP-CorV: Acute disseminated encephalomyelitis: case report
Publicado: (2022)

BBIBP-CorV: Stevens-Johnson syndrome: case report
Publicado: (2022)

BBIBP-CorV: Stevens-Johnson-syndrome: case report
Publicado: (2022)

Heterologous booster response after inactivated virus BBIBP-CorV vaccination in older people
por: Rouco, Santiago Oviedo, et al.
Publicado: (2022)

BBIBP-CorV/tozinameran: Subacute thyroiditis: 2 case reports
Publicado: (2022)

BBIBP-CorV: Adult multisystem inflammatory syndrome: case report
Publicado: (2021)

BBIBP-CorV: Eye disorders and hypertension: 7 case reports
Publicado: (2021)

Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2
por: Wang, Hui, et al.
Publicado: (2020)

Safety and Immunogenicity of COVID-19 BBIBP-CorV Vaccine in Children 3–12 Years Old
por: Greish, Khaled, et al.
Publicado: (2022)

Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals
por: Mallah, Saad I., et al.
Publicado: (2023)

BBIBP-CorV: Vaccine-induced immune thrombotic thrombocytopenia: case report
Publicado: (2022)

Thrombotic thrombocytopenia After Sinopharm BBIBP‐CorV COVID‐19 vaccination
por: Hosseinzadeh, Rezvan, et al.
Publicado: (2022)

Antibody responses to Sinopharm/BBIBP-CorV in pregnant mothers in Sri Lanka
por: Jeewandara, Chandima, et al.
Publicado: (2022)

Case Report: Subacute thyroiditis after receiving inactivated SARS-CoV-2 vaccine (BBIBP-CorV)
por: Pi, Linhua, et al.
Publicado: (2022)

Immune response and homeostasis mechanism following administration of BBIBP-CorV SARS-CoV-2 inactivated vaccine
por: Yin, Jianhua, et al.
Publicado: (2022)

Guillain-Barré Syndrome Following the First Dose of Inactivated SARS-CoV-2 Vaccine, BBIBP-CorV
por: Wijekoon, Lanka, et al.
Publicado: (2023)

Immunogenicity and safety of the BBIBP‐CorV vaccine in patients with autoimmune inflammatory rheumatic diseases undergoing immunosuppressive therapy in a monocentric cohort
por: Zamani, Batool, et al.
Publicado: (2023)

Vaccination with the Inactivated Vaccine (Sinopharm BBIBP-CorV) Ensures Protection against SARS-CoV-2 Related Disease
por: Wang, Chao, et al.
Publicado: (2022)

Abducense nerve palsy following BBIBP-CorV (Sinopharm) COVID-19 vaccine
por: Khalili, M.R., et al.
Publicado: (2022)

Correlation of gut microbiota and metabolic functions with the antibody response to the BBIBP-CorV vaccine
por: Tang, Bo, et al.
Publicado: (2022)

Cord blood antibodies following BBIBP‐CorV (Sinopharm) vaccination during pregnancy
por: Hantoushzadeh, Sedigheh, et al.
Publicado: (2023)

Safety and Immunogenicity of the BBIBP-CorV Vaccine in Adolescents Aged 12 to 17 Years in the Thai Population: An Immunobridging Study
por: Tawinprai, Kriangkrai, et al.
Publicado: (2022)

SG-APSIC1049: Immunogenicity of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines in seropositive and seronegative adults
por: Stoma, Igor, et al.
Publicado: (2023)

Evaluation of SARS-CoV-2 Serum Level in Patients Vaccinated With Sinopharm/BBIBP-CorV With Kidney Transplantation
por: Rahbar, Maryam, et al.
Publicado: (2022)

BBIBP-CorV/SARS-COV-2-vaccine-inactivated-Sinovac-Biotech: Eye disorders: 7 case reports
Publicado: (2022)

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
por: Xia, Shengli, et al.
Publicado: (2021)

BBIBP-CorV Vaccination against the SARS-CoV-2 Virus Affects the Gut Microbiome
por: Shen, Yang, et al.
Publicado: (2023)

SARS-CoV-2-specific T Cell Immunity after Vaccination with Sputnik V and BBIBP-CorV
por: Babrukevich, Darya, et al.
Publicado: (2022)

Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial
por: Kaabi, Nawal Al, et al.
Publicado: (2022)

Comparative immunogenicity and safety of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines: results of a pilot clinical study
por: Stoma, Igor, et al.
Publicado: (2023)

Persistence of antibody and T cell responses to the Sinopharm/BBIBP-CorV vaccine in Sri Lankan individuals
por: Jeewandara, Chandima, et al.
Publicado: (2021)

Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine
por: Chansaenroj, Jira, et al.
Publicado: (2022)

BBIBP-CorV/SARS-COV-2-vaccine-inactivated-Sinovac-Biotech: Cerebral venous thrombosis: 4 case reports
Publicado: (2022)

Evaluation of the Efficacy of BBIBP-CorV Inactivated Vaccine Combined with BNT62b2 mRNA Booster Vaccine
por: Rákóczi, Éva, et al.
Publicado: (2023)

Neutralization of five SARS-CoV-2 variants of concern by convalescent and BBIBP-CorV vaccinee serum
por: Zhu, Yuqi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ur5japg2sju2umfe45l823756o